Evidence map›Paper›PMID 42891079›Full record

ReviewFrontiers in aging neuroscience2026

Dexmedetomidine as a potential neuroprotective agent against Alzheimer's disease: molecular mechanisms and therapeutic perspectives.

Jun Kang, Yongbo Duan, Jiaxuan Bi, Jiangping Liu, Wenjun Yan

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in aging neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jun KangFirst Clinical Medical College of Lanzhou University, Lanzhou, China.
Yongbo DuanFirst Clinical Medical College of Lanzhou University, Lanzhou, China.
Jiaxuan BiDepartment of Anesthesiology, Gansu Provincial Hospital, Lanzhou, China.
Jiangping LiuInstitute of Clinical Research and Translational Medicine, Gansu Provincial Hospital, Lanzhou, China.
Wenjun YanFirst Clinical Medical College of Lanzhou University, Lanzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's disease (AD) is a neurodegenerative disorder characterized by extracellular deposition of amyloid-β (Aβ), intracellular hyperphosphorylation of microtubule-associated protein tau and chronic neuroinflammation. At present, effective disease-modifying therapies for AD remain limited. Dexmedetomidine (Dex), a highly selective α

Indexed as

Alzheimer’s diseaseamyloid-βdexmedetomidineneuroinflammationneuroprotection

Identifiers

PMID42891079
PMCPMC13673236

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.